Business Context and Reporting Period
Company: Evotec SE (Evotec AG)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fiscal Year Ended December 31, 2008
Filing Date: March 27, 2009
Evotec AG is a drug discovery and development company focused on novel small molecule therapeutics for neuroscience, pain, and inflammation. The filing reports full-year 2008 financial results and announces a strategic restructuring plan titled "Evotec 2012 Action Plan to Focus and Grow." The company completed the acquisition of Renovis, Inc. in May 2008 and divested its Chemical Development Business in late 2007.
Key Financial Metrics
| Metric | 2008 (T€) | 2007 (T€) | Change |
|---|---|---|---|
| Revenues | 39.6 | 32.9 | +20% |
| Gross Margin | 44.5% | 24.4% | +20.1 pts |
| Operating Loss | (73.2) | (58.1) | -26% |
| Net Loss | (78.3) | (48.1) | -63% |
| Cash & Investments | 92.4 | 93.7 | -1% |
| Debt (Total) | 11.3 | 11.7 | -3% |
Note: All figures in thousands of Euros (T€). 2007 figures reflect continuing operations only.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by €8.5 million in milestone payments from the Boehringer Ingelheim collaboration. Underlying research collaboration revenues remained flat due to currency headwinds and the absence of library synthesis revenues following a joint venture transfer.
- Increased Operating Loss: Despite a significant rise in gross profit, the operating loss widened due to:
- Impairment Charges: Non-cash impairments totaling €27.6 million (€20.3m goodwill, €7.3m intangible assets) resulting from a decision to discontinue earlier discovery projects to reduce R&D spend.
- R&D Expenses: Increased 15% to €42.5 million, driven by the inclusion of Renovis costs and a €2.7 million milestone payment to Roche for EVT 302.
- SG&A Expenses: Increased 12% to €20.0 million due to Renovis integration, Sarbanes-Oxley compliance, and severance payments.
- Net Loss Drivers: The net loss increase was exacerbated by a non-cash foreign exchange loss of €11.8 million related to a capital reserve reduction in a UK subsidiary and income taxes of €1.9 million. These were partially offset by €4.6 million in income from the sale of DIREVO convertible bonds.
Guidance, Outlook, and Strategic Changes
Strategic Restructuring ("Evotec 2012")
Management announced a plan to significantly reduce costs and focus on core assets to extend cash reach beyond 2012. Key actions include:
- Cost Reductions: SG&A expenses to decrease by >10% and R&D costs by >30% (approx. €14 million reduction vs. 2008).
- Headcount: Immediate reduction of approximately 50 positions, bringing total workforce to below 370.
- Pipeline Focus: Concentration on four core value assets: EVT 302 (smoking cessation), EVT 101 (depression, partnered with Roche), P2X7 antagonist (inflammation), and VR1 antagonist (pain, partnered with Pfizer).
2009 Financial Guidance
- Revenues: Expected to reach €35 million (excluding out-licensing income).
- R&D Expenses: Targeted below €30 million.
- Operating Result: Expected to improve significantly over 2008 (excluding impairment charges).
- Liquidity: Starting with €92.4 million, the company expects funds to be sufficient for operations over more than three years, with year-end 2009 liquidity projected to exceed €65 million.
Risks and Contingencies
- Partnering Delays: Failure to secure a partner for the insomnia drug candidate EVT 201 in 2008; internal investment in this program has been stopped.
- Currency Risk: Significant exposure to USD and GBP fluctuations against the Euro.
- Auction Rate Securities (ARS): Holdings of €8.3 million in ARS are currently illiquid due to market failures, though interest payments continue.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the €92.4 million cash position against the revised €30 million R&D budget and the timeline for the "Evotec 2012" cost savings.
- Impairment Validity: Assess the rationale for the €27.6 million impairment charge and the specific projects discontinued to ensure no further write-downs are imminent.
- ARS Exposure: Confirm the status of the €8.3 million in illiquid Auction Rate Securities and the valuation of the associated put option.
- Roche Partnership: Monitor the progress of the Phase II trial for EVT 101 (depression) and the potential for the €65 million buyback option.
- EVT 302 Data: Track the mid-2009 results of the Phase II proof-of-concept study for smoking cessation, a key value driver.